Dual Metabolic Reprogramming to Enhance Ferroptotic Therapy in TNBC

Study Background and Research Question

Triple-negative breast cancer (TNBC) represents one of the most aggressive and therapeutically challenging subtypes of breast cancer, accounting for 15–20% of clinical cases globally. TNBC is defined by the absence of estrogen, progesterone, and HER2 receptors, limiting the effectiveness of targeted therapies and making chemotherapy the primary, yet often insufficient, treatment option. As TNBC frequently acquires resistance to apoptosis-induced cell death, alternative strategies are urgently required. Ferroptosis, an iron-dependent form of regulated cell death driven by lethal accumulation of lipid peroxides, has emerged as a promising avenue for selectively eradicating apoptosis-resistant cancer cells. However, intrinsic and adaptive mechanisms of ferroptosis resistance, particularly via compensatory metabolic pathways, significantly limit the clinical translation of ferroptosis-based therapies. The reference study (Journal of Colloid and Interface Science, 2026) specifically interrogates how dual targeting of key metabolic axes can overcome these resistance mechanisms in TNBC.

Key Innovation from the Reference Study

The primary innovation of the study lies in the fabrication of a metal-polyphenol nanoplatform capable of synchronously inhibiting both dihydroorotate dehydrogenase (DHODH) and diacylglycerol O-acyltransferase 1 (DGAT1) in TNBC cells. Previous approaches have targeted GPX4, a critical enzyme in ferroptosis defense, but compensatory upregulation of DHODH has limited efficacy. The current work demonstrates that while DHODH inhibition (using brequinar, BQR) sensitizes cells to ferroptosis via disrupted redox balance and pyrimidine metabolism, it paradoxically induces lipid droplet (LD) accumulation, which in turn increases ferroptosis resistance. By incorporating a DGAT1 inhibitor (A922500) into the same nanoplatform, the authors achieve dual metabolic reprogramming: they block both the nucleotide and lipid metabolic escape routes, thereby maximizing ferroptosis susceptibility in TNBC cells. This dual strategy represents a significant advancement over monotherapy approaches and provides a blueprint for next-generation ferroptosis-integrated combination therapies.

Methods and Experimental Design Insights

The study employed a 'one-pot' synthesis to construct a nanodelivery system (AB@HA-TA/Fe) encapsulating both BQR and A922500 within a metal-polyphenol network. Hyaluronic acid (HA) was used for tumor targeting, while tannic acid (TA) and Fe(III) provided the polyphenol and metal framework, respectively. The nanoplatform was characterized by size, morphology, and drug loading capacity. Cellular uptake was validated in 4T1 murine TNBC cells, and the system's ability to modulate intracellular iron, reactive oxygen species (ROS), and lipid peroxidation was assessed using established biochemical assays. In vitro cytotoxicity and ferroptosis induction were quantified via cell viability, lipid ROS, and cell cycle analysis. To evaluate therapeutic efficacy and systemic safety, in vivo studies were conducted in TNBC-bearing mouse models. The combination of dual metabolic inhibition and targeted nanodelivery was shown to be essential for recapitulating the desired therapeutic effects.

Protocol Parameters

• Nanoformulation synthesis: One-pot assembly of HA, TA, Fe(III), BQR, and A922500; optimize ratios to maximize stability and drug loading.
• Cell culture treatment: 4T1 TNBC cells exposed to AB@HA-TA/Fe (0.5–5 μM BQR equivalent) for 24–48 hours; include proper vehicle and single-drug controls.
• In vivo administration: Intravenous injection of AB@HA-TA/Fe at a dose of 5 mg/kg BQR equivalent, every other day for two weeks; monitor animal health and tumor volume.
• Assays for ferroptosis: Lipid peroxidation (C11-BODIPY), ROS generation (DCFH-DA), and cell viability (CCK-8) post-treatment.
• Lipid droplet quantification: Oil Red O staining or BODIPY 493/503 for LD visualization and quantitation post-BQR exposure.

These parameters are supported by the reference study and can be adapted based on specific laboratory resources and objectives.

Core Findings and Why They Matter

The reference study reveals that BQR-mediated DHODH inhibition in TNBC cells, while disrupting nucleotide metabolism and redox homeostasis, also triggers a compensatory increase in lipid droplet synthesis via upregulation of DGAT1. This adaptive lipid metabolic shift paradoxically protects cells from ferroptosis, thus limiting the efficacy of DHODH-targeted therapies. By co-delivering a DGAT1 inhibitor, the nanoplatform effectively blocks LD formation, thereby reversing ferroptosis resistance. Mechanistically, the AB@HA-TA/Fe nanoplatform elevates intracellular iron, boosts ROS and lipid peroxidation, and induces robust ferroptotic cell death. In vivo, this dual-targeted approach significantly suppresses tumor growth without observable systemic toxicity. These findings provide mechanistic insight into the interplay between nucleotide and lipid metabolism in ferroptosis regulation, and underscore the necessity of targeting metabolic compensation to achieve durable therapeutic responses in TNBC (see full article).

Comparison with Existing Internal Articles

Recent internal reviews, such as "Dual Metabolic Reprogramming Enhances Ferroptosis in TNBC" and "Dual Metabolic Reprogramming Enhances Ferroptosis in TNBC", have anticipated the necessity of overcoming compensatory resistance mechanisms in ferroptosis-based therapies. These articles corroborate the importance of targeting both iron and lipid metabolism, and highlight the translational potential of dual-inhibition strategies. The current reference study advances this paradigm by providing direct experimental evidence for the dual role of DHODH and DGAT1 in ferroptosis resistance, and by demonstrating the therapeutic superiority of a co-encapsulated nanoplatform. While previous resources focused on conceptual frameworks and protocol recommendations, the present study delivers preclinical validation and mechanistic clarity, bridging the gap between theory and application.

Limitations and Transferability

Despite its robust experimental design and preclinical efficacy, several limitations remain. The use of murine 4T1 models, while informative, may not fully capture the heterogeneity of human TNBC or the complexity of tumor microenvironments in patients. The pharmacokinetics, biodistribution, and potential long-term toxicity of the AB@HA-TA/Fe nanoplatform require further investigation prior to clinical translation. Additionally, the possibility of alternative compensatory pathways emerging in response to dual inhibition was not exhaustively explored. Thus, while the nanoplatform offers a compelling proof-of-concept, broader validation in diverse models and translational studies will be necessary to establish generalizability and safety profiles.

Research Support Resources

For researchers interested in advancing ferroptosis-based workflows or metabolic inhibition studies, established fluorescent reagents remain essential for precise biomarker detection and mechanistic studies. For example, DFO (9H-1,8-Diazafluoren-9-one) (SKU C6997) serves as a highly sensitive amino acid-reactive fluorescent dye for forensic and biochemical applications, particularly for latent fingerprint chemical detection on porous substrates. Its well-characterized reactivity and strong fluorescence support reliable visualization in complex matrices, as detailed in the DFO workflow reviews. When implementing advanced detection or imaging protocols related to ferroptosis or metabolic reprogramming, the use of validated reagents such as DFO can enhance experimental reproducibility and sensitivity. DFO from APExBIO is supplied at high purity, with thorough quality control documentation, and should be stored as recommended to maintain performance integrity.